Hydroxyethyl starch
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Hydroxyethyl starch?
Summarize this article for a 10 year old
Hydroxyethyl starch (HES/HAES), sold under the brand name Voluven among others, is a nonionic starch derivative, used as a volume expander in intravenous therapy. The use of HES on critically ill patients is associated with an increased risk of death and kidney problems.[2][3]
Clinical data | |
---|---|
Trade names | Hespan, Voluven, Volulyte, Tetrahes, Hestar |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 1.4 hrs |
Excretion | Renal |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.120.749 |
Chemical and physical data | |
Molar mass | 130–200 kg/mol (typical) |
3D model (JSmol) | |
| |
| |
(verify) |
HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.[4] The European Medicines Agency commenced in June 2013 the process of agreeing to reduced indications which was completed in October 2013.[5] The process of full withdrawal in the EU was expected to complete in 2018.